Iloperidone, sold as Fanapt, was approved by the FDA in 2009 for schizophrenia in adults, and in 2024 received an additional approval for acute manic or mixed episodes of bipolar I disorder. It is a relatively under-prescribed second-generation antipsychotic — partly because its slow titration requirement makes it harder to start than other options, partly because the orthostatic hypotension during initial dosing is a real management issue. For the right patient, though, it offers something genuinely valuable: one of the lowest EPS and akathisia rates among atypical antipsychotics.
Iloperidone is a serotonin–dopamine antagonist with notably low movement side effect rates but requires a 7-day titration to manage orthostatic hypotension and is taken twice daily.
Pharmacology and feel
Iloperidone has high affinity for serotonin 5-HT2A and dopamine D2 receptors, but also strong alpha-1 adrenergic blockade. The alpha-1 effect is what produces orthostatic hypotension — and is also the reason iloperidone has very low EPS rates compared with most other antipsychotics. The receptor profile gives it a generally calm, non-activating feel, sometimes mildly sedating.
The titration requirement
Per the FDA Fanapt prescribing information, iloperidone must be titrated over 7 days to reach a typical target of 12 to 24 mg/day in two divided doses. The label provides a specific schedule starting at 1 mg twice daily on day 1 and increasing roughly daily. The reason: starting at full dose causes severe orthostatic hypotension and dizziness in most patients. The 7-day window is also why iloperidone is rarely chosen for acute crises — by the time the dose is therapeutic, other agents could already be working.
Orthostatic hypotension in practice
Even with the slow titration, many patients notice lightheadedness when standing up, particularly in the first weeks. Practical strategies:
- Stand up slowly — sit on the edge of the bed for a moment first
- Stay well hydrated — at least 8 cups of water daily
- Add some salt to your diet (unless you have a reason to limit it)
- Avoid hot baths or showers, which can lower blood pressure further
- Tell your prescriber if you notice fainting or near-fainting
See our article on orthostatic hypotension.
Why the low EPS profile matters
For people who have struggled with akathisia, dystonia, or drug-induced parkinsonism on other antipsychotics, iloperidone can be a meaningful alternative. Comparative trials and meta-analyses have consistently placed it among the lowest-EPS atypicals. The trade-off is the orthostasis and the slow start.
QT prolongation
Iloperidone causes mild-to-moderate QTc prolongation. The FDA label recommends caution in combination with other QT-prolonging drugs, in patients with significant cardiac history, and with strong CYP2D6 or CYP3A4 inhibitors. A baseline ECG and electrolyte check is reasonable. See our QT prolongation article.
Metabolic profile
Weight gain on iloperidone is moderate — generally less than olanzapine, similar to risperidone. Glucose and lipid effects are present but milder than with the heaviest metabolic offenders. Standard monitoring (baseline labs, then at 3 months, 6 months, then yearly) applies.
Other side effects
- Dizziness — common, especially during titration
- Sedation — mild to moderate
- Dry mouth — common
- Nasal congestion — relatively distinctive for iloperidone, related to alpha-1 blockade
- Hyperprolactinemia — modest
- Sexual side effects — variable
You faint, develop severe chest pain, irregular heartbeat, fever with muscle stiffness, or sudden new involuntary movements.
Drug interactions
Iloperidone is metabolised by CYP2D6 and CYP3A4. Strong inhibitors of either (such as paroxetine, fluoxetine, or ketoconazole) can roughly double iloperidone levels — the label recommends halving the iloperidone dose in those situations. CYP2D6 poor metabolisers also need lower doses, and pharmacogenomic testing can help.
The 2024 bipolar I approval
In 2024, the FDA expanded iloperidone's label to include acute manic or mixed episodes of bipolar I disorder, based on a trial showing efficacy versus placebo. This makes it one of several atypicals available for bipolar mania, although the slow titration limits its use for the most acute presentations.
Who tends to do well on iloperidone
- People who have had severe EPS or akathisia on other antipsychotics
- People in stable outpatient settings where slow titration is feasible
- People who want a calmer, less activating feel than aripiprazole or brexpiprazole
- People whose insurance covers it and who can build the twice-daily routine
Who might choose differently
- People in acute crisis who need rapid symptom control
- People with significant cardiovascular history or QT prolongation
- People with a history of orthostatic falls
- People who cannot reliably take twice-daily doses
Practical questions to ask your prescriber
- What does the 7-day titration look like in practice for me?
- How will we monitor blood pressure during the start?
- Should we get a baseline ECG?
- What other medications I take might interact?
- How long will we wait to judge whether it is working?
The big picture
Iloperidone is not a first-line choice in most algorithms, but it occupies a real niche. For people for whom EPS has been the dealbreaker on prior medications, the chance to take a second-generation antipsychotic with one of the lowest movement side effect rates is meaningful. The cost is patience — patience during the slow titration, patience with early orthostasis, and willingness to take it twice a day. Whether that trade-off makes sense is a conversation to have with a prescriber who knows your history.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.